{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:48:56Z","timestamp":1790686136528,"version":"4.1.0"},"reference-count":198,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Acute myeloid leukemia (AML) and myelodysplastic neoplasms (MDS) are clonal hematopoietic malignancies in which next-generation sequencing (NGS) has become integral for diagnosis, classification, risk stratification, and measurable residual disease (MRD) monitoring. Traditional cytogenetic and PCR-based assays remain useful, but targeted NGS panels now represent the standard of care, providing rapid and sensitive detection of recurrent gene mutations, structural variants, and gene fusions. Whole-genome, whole-exome, and RNA sequencing and long-read platforms expand the spectrum of detectable alterations, though targeted panels remain most practical for routine diagnostics. Bioinformatic pipelines and quality metrics\u2014including read length, sequencing depth, and coverage\u2014are critical for accurate variant calling, with validation often required for variants of uncertain significance or those near detection thresholds. NGS is now embedded in diagnostic frameworks, including the WHO 2022 and ICC classifications, which incorporate recurrently mutated genes such as TP53, ASXL1, RUNX1, and FLT3. These data inform prognostic models, with ELN-2022 defining adverse-risk AML subgroups for patients treated with intensive chemotherapy, ELN-2024 AML for patients treated with less-intensive therapies, and the IPSS-M refining MDS risk categories by integrating mutational data. NGS also enables MRD monitoring, with gene panels and PCR-NGS hybrid approaches (e.g., for FLT3-ITD) showing increasing clinical utility, though standardization is still lacking. Furthermore, diagnostic NGS frequently uncovers germline predisposition syndromes (e.g., DDX41, GATA2), with significant implications for treatment decisions and donor selection in transplantation. In this manuscript, we review the advantages, limitations, and future perspectives of NGS in the clinical management of AML and MDS with a particular emphasis on the biological and technical principles underlying its use in these diseases. Furthermore, we discuss how NGS findings may influence diagnosis, prognostic classification, and therapeutic decision-making within current clinical frameworks. Our aim is to provide a comprehensive overview of NGS fundamentals to support clinicians in navigating the increasing complexity of molecular data in daily practice.<\/jats:p>","DOI":"10.3390\/jcm14248681","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T16:20:29Z","timestamp":1765210829000},"page":"8681","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["How to Read a Next-Generation Sequencing Report for AML and MDS? What Hematologists Need to Know"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8196-0481","authenticated-orcid":false,"given":"Salvatore","family":"Perrone","sequence":"first","affiliation":[{"name":"Department of Hematology, Santa Maria Goretti Hospital, Polo Universitario Pontino, 04100 Latina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7711-5621","authenticated-orcid":false,"given":"Cristina","family":"Tresoldi","sequence":"additional","affiliation":[{"name":"Molecular Hematology Unit, IRCCS San Raffaele Scientific Institute, Via Olgettina, 60, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6391-2974","authenticated-orcid":false,"given":"Silvia","family":"Rigamonti","sequence":"additional","affiliation":[{"name":"Molecular Hematology Unit, IRCCS San Raffaele Scientific Institute, Via Olgettina, 60, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6391-4406","authenticated-orcid":false,"given":"Matteo","family":"Molica","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Azienda Ospedaliera Pugliese-Ciaccio, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1973-1121","authenticated-orcid":false,"given":"Nadezda","family":"Zhdanovskaya","sequence":"additional","affiliation":[{"name":"Hematology, Department of Translational and Precision Medicine, Sapienza University, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5642-3051","authenticated-orcid":false,"given":"Laura","family":"Cicconi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Santa Maria Goretti Hospital, Polo Universitario Pontino, 04100 Latina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic Classification and Prognosis in Acute Myeloid Leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th Edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and Management of AML in Adults: 2022 Recommendations from an International Expert Panel on Behalf of the ELN","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1182\/blood.2024025705","article-title":"How I Treat AML Relapse after Allogeneic HSCT","volume":"145","author":"Gooptu","year":"2025","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Satam, H., Joshi, K., Mangrolia, U., Waghoo, S., Zaidi, G., Rawool, S., Thakare, R.P., Banday, S., Mishra, A.K., and Das, G. (2023). Next-Generation Sequencing Technology: Current Trends and Advancements. Biology, 12.","DOI":"10.3390\/biology12070997"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"100570","DOI":"10.1016\/j.esmoop.2022.100570","article-title":"How to Read a Next-Generation Sequencing Report\u2014What Oncologists Need to Know","volume":"7","author":"Schmid","year":"2022","journal-title":"ESMO Open"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","article-title":"Recommendations for the Use of Next-Generation Sequencing (NGS) for Patients with Advanced Cancer in 2024: A Report from the ESMO Precision Medicine Working Group","volume":"35","author":"Mosele","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_8","first-page":"1269","article-title":"Emerging Technologies of Single-Cell Multi-Omics","volume":"110","author":"Kim","year":"2025","journal-title":"Haematologica"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jmoldx.2017.01.011","article-title":"Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists","volume":"19","author":"Jennings","year":"2017","journal-title":"J. Mol. Diagn."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1182\/blood.2022015853","article-title":"Genomic Profiling for Clinical Decision Making in Myeloid Neoplasms and Acute Leukemia","volume":"140","author":"Duncavage","year":"2022","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2144\/000114133","article-title":"Library Construction for Next-Generation Sequencing: Overviews and Challenges","volume":"56","author":"Head","year":"2014","journal-title":"Biotechniques"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.12717\/DR.2023.27.1.9","article-title":"The Principles and Applications of High-Throughput Sequencing Technologies","volume":"27","author":"Lee","year":"2023","journal-title":"Dev. Reprod."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nrg.2016.49","article-title":"Coming of Age: Ten Years of next-Generation Sequencing Technologies","volume":"17","author":"Goodwin","year":"2016","journal-title":"Nat. Rev. Genet."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s13046-023-02841-8","article-title":"Acute Myeloid Leukemia: From NGS, through scRNA-Seq, to CAR-T. Dissect Cancer Heterogeneity and Tailor the Treatment","volume":"42","author":"Peroni","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"O\u2019Connor, T.E., Shaw, R., Madero-Marroquin, R., and Roloff, G.W. (2023). Clinical Considerations at the Intersection of Hematopoietic Cell Transplantation and Hereditary Hematopoietic Malignancy. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1180439"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"759","DOI":"10.5858\/arpa.2016-0547-RA","article-title":"Integration of Technical, Bioinformatic, and Variant Assessment Approaches in the Validation of a Targeted Next-Generation Sequencing Panel for Myeloid Malignancies","volume":"141","author":"Thomas","year":"2017","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Akabari, R., Qin, D., and Hussaini, M. (2022). Technological Advances: CEBPA and FLT3 Internal Tandem Duplication Mutations Can Be Reliably Detected by Next Generation Sequencing. Genes, 13.","DOI":"10.3390\/genes13040630"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Cumbo, C., Minervini, C.F., Orsini, P., Anelli, L., Zagaria, A., Minervini, A., Coccaro, N., Impera, L., Tota, G., and Parciante, E. (2019). Nanopore Targeted Sequencing for Rapid Gene Mutations Detection in Acute Myeloid Leukemia. Genes, 10.","DOI":"10.3390\/genes10121026"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1146\/annurev-genom-101722-103045","article-title":"Long-Read DNA Sequencing: Recent Advances and Remaining Challenges","volume":"24","author":"Warburton","year":"2023","journal-title":"Annu. Rev. Genom. Hum. Genet."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Moustakli, E., Christopoulos, P., Potiris, A., Zikopoulos, A., Mavrogianni, D., Karampas, G., Kathopoulis, N., Anagnostaki, I., Domali, E., and Tzallas, A.T. (2025). Long-Read Sequencing and Structural Variant Detection: Unlocking the Hidden Genome in Rare Genetic Disorders. Diagnostics, 15.","DOI":"10.3390\/diagnostics15141803"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nrg3642","article-title":"Sequencing Depth and Coverage: Key Considerations in Genomic Analyses","volume":"15","author":"Sims","year":"2014","journal-title":"Nat. Rev. Genet."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1055\/s-0045-1806726","article-title":"Uniform Reporting of Next Generation Sequencing: Indian Society of Medical and Pediatric Oncology","volume":"46","author":"Anu","year":"2025","journal-title":"Indian J. Med. Paediatr. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Conesa, A., Madrigal, P., Tarazona, S., Gomez-Cabrero, D., Cervera, A., McPherson, A., Szczesniak, M.W., Gaffney, D.J., Elo, L.L., and Zhang, X. (2016). A Survey of Best Practices for RNA-Seq Data Analysis. Genome Biol., 17.","DOI":"10.1186\/s13059-016-0881-8"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2018.203133","article-title":"Targeted RNA-Sequencing for the Quantification of Measurable Residual Disease in Acute Myeloid Leukemia","volume":"104","author":"Dillon","year":"2019","journal-title":"Haematologica"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/cts.12511","article-title":"Whole Transcriptome Profiling: An RNA-Seq Primer and Implications for Pharmacogenomics Research","volume":"11","author":"Sa","year":"2018","journal-title":"Clin. Transl. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Baccarella, A., Williams, C.R., Parrish, J.Z., and Kim, C.C. (2018). Empirical Assessment of the Impact of Sample Number and Read Depth on RNA-Seq Analysis Workflow Performance. BMC Bioinform., 19.","DOI":"10.1186\/s12859-018-2445-2"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/s41467-017-01470-y","article-title":"Prevalence and Detection of Low-Allele-Fraction Variants in Clinical Cancer Samples","volume":"8","author":"Shin","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Petrackova, A., Vasinek, M., Sedlarikova, L., Dyskova, T., Schneiderova, P., Novosad, T., Papajik, T., and Kriegova, E. (2019). Standardization of Sequencing Coverage Depth in NGS: Recommendation for Detection of Clonal and Subclonal Mutations in Cancer Diagnostics. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.00851"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Singh, R.R. (2022). Target Enrichment Approaches for Next-Generation Sequencing Applications in Oncology. Diagnostics, 12.","DOI":"10.3390\/diagnostics12071539"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jmoldx.2025.01.002","article-title":"Clinical Validation of the TruSight Oncology 500 Assay for the Detection and Reporting of Pan-Cancer Biomarkers","volume":"27","author":"Knight","year":"2025","journal-title":"J. Mol. Diagn."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Sahajpal, N.S., Mondal, A.K., Ananth, S., Njau, A., Ahluwalia, P., Jones, K., Ahluwalia, M., Okechukwu, N., Savage, N.M., and Kota, V. (2020). Clinical Performance and Utility of a Comprehensive Next-Generation Sequencing DNA Panel for the Simultaneous Analysis of Variants, TMB and MSI for Myeloid Neoplasms. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0240976"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"7355","DOI":"10.2147\/OTT.S99807","article-title":"Next-Generation Sequencing: Advances and Applications in Cancer Diagnosis","volume":"9","author":"Serrati","year":"2016","journal-title":"Onco Targets Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13073-020-00791-w","article-title":"Best Practices for Variant Calling in Clinical Sequencing","volume":"12","author":"Koboldt","year":"2020","journal-title":"Genome Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/leu.2016.160","article-title":"Ordering of Mutations in Acute Myeloid Leukemia with Partial Tandem Duplication of MLL (MLL-PTD)","volume":"31","author":"Sun","year":"2017","journal-title":"Leukemia"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jmoldx.2012.08.001","article-title":"Detection of FLT3 Internal Tandem Duplication in Targeted, Short-Read-Length, next-Generation Sequencing Data","volume":"15","author":"Spencer","year":"2013","journal-title":"J. Mol. Diagn."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Aguilera-Diaz, A., Vazquez, I., Ariceta, B., Manu, A., Blasco-Iturri, Z., Palomino-Echeverria, S., Larrayoz, M.J., Garcia-Sanz, R., Prieto-Conde, M.I., and Del Carmen Chillon, M. (2020). Assessment of the Clinical Utility of Four NGS Panels in Myeloid Malignancies. Suggestions for NGS Panel Choice or Design. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0227986"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1182\/blood.2019002180","article-title":"FLT3 Inhibitors Added to Induction Therapy Induce Deeper Remissions","volume":"135","author":"Levis","year":"2020","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"959","DOI":"10.5858\/arpa.2019-0352-CP","article-title":"Proficiency Testing of Standardized Samples Shows High Interlaboratory Agreement for Clinical Next Generation Sequencing-Based Hematologic Malignancy Assays with Survey Material-Specific Differences in Variant Frequencies","volume":"144","author":"Keegan","year":"2020","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13000-022-01202-x","article-title":"A Comparative Study of Next-Generation Sequencing and Fragment Analysis for the Detection and Allelic Ratio Determination of FLT3 Internal Tandem Duplication","volume":"17","author":"Kim","year":"2022","journal-title":"Diagn. Pathol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/MPH.0000000000002840","article-title":"Acute Myeloid Leukemia and Next-Generation Sequencing Panels for Diagnosis: A Comprehensive Review","volume":"46","author":"Chaudhary","year":"2024","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Hobeck, A.D., Wendt, S., Krohn, S., Knuebel, G., Bartels, S., Schipper, E., Junghanss, C., and Murua Escobar, H. (2024). Comparative Analyses of Targeted Myeloid Cancer Next-Generation Sequencing Panel in Fresh Blood, Bone Marrow and FFPE Material. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25063534"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.annonc.2020.11.002","article-title":"Myelodysplastic Syndromes: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up(\u2020\u2606)","volume":"32","author":"Fenaux","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"8091746","DOI":"10.1155\/2022\/8091746","article-title":"Concordance of Peripheral Blood and Bone Marrow Next-Generation Sequencing in Hematologic Neoplasms","volume":"2022","author":"Jumniensuk","year":"2022","journal-title":"Adv. Hematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1182\/bloodadvances.2020002306","article-title":"Mutational Analysis of Hematologic Neoplasms in 164 Paired Peripheral Blood and Bone Marrow Samples by Next-Generation Sequencing","volume":"4","author":"Lucas","year":"2020","journal-title":"Blood Adv."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e38556","DOI":"10.1097\/MD.0000000000038556","article-title":"NGS Panel Enhance Precise Diagnosis of Myeloid Neoplasms under WHO-HAEM5 and International Consensus Classification: An Observational Study","volume":"103","author":"Ye","year":"2024","journal-title":"Medicine"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists","volume":"19","author":"Li","year":"2017","journal-title":"J. Mol. Diagn."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating Morphologic, Clinical, and Genomic Data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3324\/haematol.2022.282442","article-title":"Advances in Next-Generation Sequencing and Emerging Technologies for Hematologic Malignancies","volume":"109","author":"Kwon","year":"2024","journal-title":"Haematologica"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Horgan, D., Curigliano, G., Riess, O., Hofman, P., Buttner, R., Conte, P., Cufer, T., Gallagher, W.M., Georges, N., and Kerr, K. (2022). Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe. J. Pers. Med., 12.","DOI":"10.3390\/jpm12010072"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e943","DOI":"10.1097\/HS9.0000000000000943","article-title":"Targeted High-Throughput Sequencing for Hematological Malignancies: A GBMHM Survey of Practice and Cost Evaluation in France","volume":"7","author":"Darlington","year":"2023","journal-title":"Hemasphere"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.gim.2022.01.001","article-title":"Standards for the Classification of Pathogenicity of Somatic Variants in Cancer (Oncogenicity): Joint Recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC)","volume":"24","author":"Horak","year":"2022","journal-title":"Genet. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Med."},{"key":"ref_53","unstructured":"(2015). Quality Management Systems\u2014Requirements (Standard No. ISO 9001:2015)."},{"key":"ref_54","unstructured":"(2022). Medical Laboratories\u2014Requirements for Quality and Competence (Standard No. ISO 15189:2022)."},{"key":"ref_55","unstructured":"(2018). General Requirements for the Competence of Testing and Calibration Laboratories (Standard No. UNI CEI EN ISO\/IEC 17025:2018)."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00428-024-03951-0","article-title":"Reporting of Somatic Variants in Clinical Cancer Care: Recommendations of the Swiss Society of Molecular Pathology","volume":"485","author":"Christinat","year":"2024","journal-title":"Virchows Arch."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Galimberti, S., Balducci, S., Guerrini, F., Del Re, M., and Cacciola, R. (2022). Digital Droplet PCR in Hematologic Malignancies: A New Useful Molecular Tool. Diagnostics, 12.","DOI":"10.3390\/diagnostics12061305"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/nmeth.2633","article-title":"Absolute Quantification by Droplet Digital PCR versus Analog Real-Time PCR","volume":"10","author":"Hindson","year":"2013","journal-title":"Nat. Methods"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41408-018-0148-6","article-title":"Challenges in the Introduction of Next-Generation Sequencing (NGS) for Diagnostics of Myeloid Malignancies into Clinical Routine Use","volume":"8","author":"Bacher","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Panuzzo, C., Jovanovski, A., Ali, M.S., Cilloni, D., and Pergolizzi, B. (2022). Revealing the Mysteries of Acute Myeloid Leukemia: From Quantitative PCR through Next-Generation Sequencing and Systemic Metabolomic Profiling. J. Clin. Med., 11.","DOI":"10.3390\/jcm11030483"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1007\/s12094-023-03195-5","article-title":"Real-World Genomic Profiling of Acute Myeloid Leukemia and the Impact of European LeukemiaNet Risk Stratification 2022 Update","volume":"25","author":"Silveira","year":"2023","journal-title":"Clin. Transl. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 Revision to the World Health Organization Classification of Myeloid Neoplasms and Acute Leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1038\/s41375-022-01718-7","article-title":"Comparison of the Revised 4th (2016) and 5th (2022) Editions of the World Health Organization Classification of Myelodysplastic Neoplasms","volume":"36","author":"Zhang","year":"2022","journal-title":"Leukemia"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"DeZern, A.E., Malcovati, L., and Ebert, B.L. (2018). CHIP, CCUS, and Other Acronyms: Definition, Implications, and Impact on Practice. American Society of Clinical Oncology Educational Book, American Society of Clinical Oncology (ASCO).","DOI":"10.1200\/EDBK_239083"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41569-025-01148-9","article-title":"Clonal Haematopoiesis in Cardiovascular Disease: Prognostic Role and Novel Therapeutic Target","volume":"22","author":"Schuermans","year":"2025","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1182\/blood.2024024756","article-title":"Risk Prediction for Clonal Cytopenia: Multicenter Real-World Evidence","volume":"144","author":"Xie","year":"2024","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1038\/s41375-024-02273-z","article-title":"Genomic Landscape of CCUS Compared to MDS and Its Implications on Risk Prediction","volume":"38","author":"Huber","year":"2024","journal-title":"Leukemia"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1182\/blood-2017-01-763425","article-title":"Clinical Significance of Somatic Mutation in Unexplained Blood Cytopenia","volume":"129","author":"Malcovati","year":"2017","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","article-title":"Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts","volume":"365","author":"Papaemmanuil","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"6239","DOI":"10.1182\/blood-2011-09-377275","article-title":"Clinical Significance of SF3B1 Mutations in Myelodysplastic Syndromes and Myelodysplastic\/Myeloproliferative Neoplasms","volume":"118","author":"Malcovati","year":"2011","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of Genetic Lesions in 944 Patients with Myelodysplastic Syndromes","volume":"28","author":"Haferlach","year":"2014","journal-title":"Leukemia"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","article-title":"Implications of TP53 Allelic State for Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes","volume":"26","author":"Bernard","year":"2020","journal-title":"Nat. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1182\/bloodadvances.2024014140","article-title":"Diagnosis of TP53-Mutated Myeloid Disease by the ICC and WHO Fifth Edition Classifications","volume":"9","author":"Hart","year":"2025","journal-title":"Blood Adv."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1038\/s41375-024-02267-x","article-title":"ERIC Recommendations for TP53 Mutation Analysis in Chronic Lymphocytic Leukemia\u20142024 Update","volume":"38","author":"Malcikova","year":"2024","journal-title":"Leukemia"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.3324\/haematol.2017.172544","article-title":"Favorable Impact of Allogeneic Stem Cell Transplantation in Patients with Therapy-Related Myelodysplasia Regardless of TP53 Mutational Status","volume":"102","author":"Aldoss","year":"2017","journal-title":"Haematologica"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical Effect of Point Mutations in Myelodysplastic Syndromes","volume":"364","author":"Bejar","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute Myeloid Leukemia Ontogeny Is Defined by Distinct Somatic Mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1182\/blood-2011-12-399774","article-title":"Mutations in the Spliceosome Machinery, a Novel and Ubiquitous Pathway in Leukemogenesis","volume":"119","author":"Makishima","year":"2012","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Visconte, V., Nakashima, M.O., and Rogers, H.J. (2019). Mutations in Splicing Factor Genes in Myeloid Malignancies: Significance and Impact on Clinical Features. Cancers, 11.","DOI":"10.3390\/cancers11121844"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3324\/haematol.2014.114157","article-title":"ASXL1 Mutations in Younger Adult Patients with Acute Myeloid Leukemia: A Study by the German-Austrian Acute Myeloid Leukemia Study Group","volume":"100","author":"Paschka","year":"2015","journal-title":"Haematologica"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.3324\/haematol.2019.222323","article-title":"EZH2 Mutations and Impact on Clinical Outcome: An Analysis in 1,604 Patients with Newly Diagnosed Acute Myeloid Leukemia","volume":"105","author":"Stasik","year":"2020","journal-title":"Haematologica"},{"key":"ref_85","first-page":"1646","article-title":"Be Aware of the X: BCOR Mutations in Myeloid Neoplasms","volume":"109","author":"Ramil","year":"2024","journal-title":"Haematologica"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41408-023-00790-1","article-title":"Alterations of Cohesin Complex Genes in Acute Myeloid Leukemia: Differential Co-Mutations, Clinical Presentation and Impact on Outcome","volume":"13","author":"Eckardt","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Molica, M., Perrone, S., Mazzone, C., Cesini, L., Canichella, M., and de Fabritiis, P. (2022). CPX-351: An Old Scheme with a New Formulation in the Treatment of High-Risk AML. Cancers, 14.","DOI":"10.3390\/cancers14122843"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1200\/JCO.2010.30.7926","article-title":"RUNX1 Mutations in Acute Myeloid Leukemia: Results from a Comprehensive Genetic and Clinical Analysis from the AML Study Group","volume":"29","author":"Gaidzik","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1182\/blood.2020009680","article-title":"CEBPA Mutations in 4708 Patients with Acute Myeloid Leukemia: Differential Impact of bZIP and TAD Mutations on Outcome","volume":"139","author":"Taube","year":"2022","journal-title":"Blood"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1182\/blood-2023-179651","article-title":"Clinical Features and Monitoring of Germline CEBPA-Mutated Carriers","volume":"142","author":"Pan","year":"2023","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41375-024-02476-4","article-title":"Functions of the Native NPM1 Protein and Its Leukemic Mutant","volume":"39","author":"Falini","year":"2025","journal-title":"Leukemia"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1182\/blood.2019004226","article-title":"NPM1-Mutated Acute Myeloid Leukemia: From Bench to Bedside","volume":"136","author":"Falini","year":"2020","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.24.00826","article-title":"Menin Inhibition with Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)","volume":"43","author":"Issa","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"104783","DOI":"10.1016\/j.critrevonc.2025.104783","article-title":"Menin Inhibitors in KMT2A-Rearranged and NPM1-Mutated Acute Leukemia: A Scoping Review of Safety and Efficacy","volume":"213","author":"Dali","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1182\/blood.2025028357","article-title":"Menin Inhibition with Revumenib for NPM1-Mutated Relapsed or Refractory Acute Myeloid Leukemia: The AUGMENT-101 Study","volume":"146","author":"Arellano","year":"2025","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1097\/01.HS9.0000850020.71791.8d","article-title":"PB1792: NGS vs PCR for the detection of npm1 gene mutations in acute myeloid leukemia","volume":"6","author":"Severina","year":"2022","journal-title":"Hemasphere"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1182\/bloodadvances.2024014490","article-title":"Advantages of a Genomic DNA-Based next-Generation Sequencing Assay for Detection of Mutant NPM1 Measurable Residual Disease in AML","volume":"9","author":"Vonk","year":"2025","journal-title":"Blood Adv."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Boluda, B., Rodriguez-Veiga, R., Sargas, C., Ayala, R., Larr\u00e1yoz, M.J., Chill\u00f3n, M.C., Soria-Saldise, E., Bilbao, C., Prados De La Torre, E.P., and Navarro, I. (2025). Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Results of the PETHEMA PCR-LMA Study. Cancers, 17.","DOI":"10.3390\/cancers17050854"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1007\/s00508-024-02463-w","article-title":"Acute Myeloid Leukemia in the Next-Generation Sequencing Era: Real-World Data from an Austrian Tertiary Cancer Care Center","volume":"137","author":"Wurm","year":"2024","journal-title":"Wien. Klin. Wochenschr."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"11607","DOI":"10.1182\/blood-2022-169767","article-title":"How Often Do Cytogenetics and NGS Information Impact Upfront Treatment in AML?","volume":"140","author":"Akabane","year":"2022","journal-title":"Blood"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/ajh.27625","article-title":"Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management","volume":"100","author":"Shimony","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_102","unstructured":"(2025, October 25). Resources for Information|Approved Drugs. FDA Approves Ivosidenib for Myelodysplastic Syndromes, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ivosidenib-myelodysplastic-syndromes."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus Chemotherapy in Newly Diagnosed Patients with FLT3-Internal-Tandem-Duplication-Positive Acute Myeloid Leukaemia (QuANTUM-First): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Petermichl, V., Fuchs, S., Weber, M., Gobat, K., Micheloud, C., Graf, L., Gerth, Y., Goede, J.S., Lehmann, T., and Driessen, C. (2025). Prognostic Impact of the AML60+ Score for Elderly Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Retrospective Multicentric Analysis. Cancers, 17.","DOI":"10.3390\/cancers17162658"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41408-022-00700-x","article-title":"A Scoring System for AML Patients Aged 70 Years or Older, Eligible for Intensive Chemotherapy: A Study Based on a Large European Data Set Using the DATAML, SAL, and PETHEMA Registries","volume":"12","author":"Bertoli","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_108","first-page":"536","article-title":"Artificial Intelligence-Based Myelodysplastic Syndromes Score, 2022 Classifications, and the Molecular International Prognostic Scoring System: A Perfect Match","volume":"110","author":"Clichet","year":"2024","journal-title":"Haematologica"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and Management of AML in Adults: 2017 ELN Recommendations from an International Expert Panel","volume":"129","author":"Estey","year":"2017","journal-title":"Blood"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/ajh.26984","article-title":"Myelodysplastic Syndromes: 2023 Update on Diagnosis, Risk-Stratification, and Management","volume":"98","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised International Prognostic Scoring System for Myelodysplastic Syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1200\/JCO.2012.48.0764","article-title":"Revised International Prognostic Scoring System (IPSS) Predicts Survival and Leukemic Evolution of Myelodysplastic Syndromes Significantly Better Than IPSS and WHO Prognostic Scoring System: Validation by the Gruppo Romano Mielodisplasie Italian Regional Database","volume":"31","author":"Voso","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"EVIDoa2200008","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular International Prognostic Scoring System for Myelodysplastic Syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1200\/JCO.22.01784","article-title":"Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes","volume":"41","author":"Sauta","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41408-023-00894-8","article-title":"Validation of the Molecular International Prognostic Scoring System in Patients with Myelodysplastic Syndromes Defined by International Consensus Classification","volume":"13","author":"Lee","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/s41375-023-01831-1","article-title":"Risk Prediction in MDS: Independent Validation of the IPSS-M\u2014Ready for Routine?","volume":"37","author":"Baer","year":"2023","journal-title":"Leukemia"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Zamanillo, I., Poza, M., Ayala, R., Rapado, I., Martinez-Lopez, J., and Cedena, M.T. (2023). Impact of IPSS-M Implementation in Real-Life Clinical Practice. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1199023"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1200\/JCO.23.02175","article-title":"Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients with Myelodysplastic Syndromes","volume":"42","author":"Tentori","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Bill, M., Eckardt, J.-N., D\u00f6hner, K., R\u00f6hnert, M.-A., Rausch, C., Metzeler, K.H., Spiekermann, K., Stasik, S., Wurm, A.A., and Sauer, T. (2025). Differential Prognostic Impact of Myelodysplasia-Related Gene Mutations in a European Cohort of 4978 Intensively Treated AML Patients. Leukemia, 1\u20139.","DOI":"10.1038\/s41375-025-02781-6"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1016\/S2352-3026(23)00305-8","article-title":"Indication and Management of Allogeneic Haematopoietic Stem-Cell Transplantation in Myelofibrosis: Updated Recommendations by the EBMT\/ELN International Working Group","volume":"11","author":"Bacigalupo","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1182\/bloodadvances.2023010179","article-title":"Guadecitabine vs Treatment Choice in Newly Diagnosed Acute Myeloid Leukemia: A Global Phase 3 Randomized Study","volume":"7","author":"Fenaux","year":"2023","journal-title":"Blood Adv."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41409-024-02493-y","article-title":"Editorial: Molecular MRD Testing in Patients with Acute Myeloid Leukemia","volume":"60","author":"Blackmon","year":"2025","journal-title":"Bone Marrow Transpl."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood.2023022226","article-title":"MRD in AML: Who, What, When, Where, and How?","volume":"143","author":"Sahasrabudhe","year":"2024","journal-title":"Blood"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1507471","article-title":"Assessment of Minimal Residual Disease in Standard-Risk AML","volume":"374","author":"Ivey","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1182\/bloodadvances.2018023432","article-title":"NPM1 Mutated AML Can Relapse with Wild-Type NPM1: Persistent Clonal Hematopoiesis Can Drive Relapse","volume":"2","author":"Meggendorfer","year":"2018","journal-title":"Blood Adv."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1038\/s41467-019-09745-2","article-title":"Clonal Evolution Patterns in Acute Myeloid Leukemia with NPM1 Mutation","volume":"10","author":"Cocciardi","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"108466","DOI":"10.1016\/j.mrrev.2023.108466","article-title":"Error-Corrected next Generation Sequencing\u2014Promises and Challenges for Genotoxicity and Cancer Risk Assessment","volume":"792","author":"Marchetti","year":"2023","journal-title":"Mutat. Res. Rev. Mutat. Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/elps.202400202","article-title":"Enhanced Error Suppression for Accurate Detection of Low-Frequency Variants","volume":"46","author":"Chen","year":"2025","journal-title":"Electrophoresis"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/MOH.0000000000000626","article-title":"Genetic Heterogeneity and Clonal Evolution in Acute Myeloid Leukemia","volume":"28","author":"Meyer","year":"2021","journal-title":"Curr. Opin. Hematol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.ccell.2020.11.011","article-title":"Dissecting Clonal Heterogeneity in AML","volume":"38","author":"Schuringa","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1158\/2159-8290.CD-18-1453","article-title":"Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia","volume":"9","author":"McMahon","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41375-023-02084-8","article-title":"Perspective on Measurable Residual Disease Testing in Acute Myeloid Leukemia","volume":"38","author":"Walter","year":"2024","journal-title":"Leukemia"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1182\/blood.2024025154","article-title":"Measurable Residual Disease and Posttransplantation Gilteritinib Maintenance for Patients with FLT3-ITD-Mutated AML","volume":"145","author":"Levis","year":"2025","journal-title":"Blood"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/bloodadvances.2020003738","article-title":"Clinical Implications of Sequential MRD Monitoring by NGS at 2 Time Points after Chemotherapy in Patients with AML","volume":"5","author":"Tsai","year":"2021","journal-title":"Blood Adv."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood.V100.1.59","article-title":"Analysis of FLT3 Length Mutations in 1003 Patients with Acute Myeloid Leukemia: Correlation to Cytogenetics, FAB Subtype, and Prognosis in the AMLCG Study and Usefulness as a Marker for the Detection of Minimal Residual Disease","volume":"100","author":"Schnittger","year":"2002","journal-title":"Blood"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/gcc.21955","article-title":"Next-Generation Sequencing for Minimal Residual Disease Monitoring in Acute Myeloid Leukemia Patients with FLT3-ITD or NPM1 Mutations","volume":"51","author":"Thol","year":"2012","journal-title":"Genes. Chromosomes Cancer"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.23.02474","article-title":"Gilteritinib as Post-Transplant Maintenance for AML with Internal Tandem Duplication Mutation of FLT3","volume":"42","author":"Levis","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/jama.2023.1363","article-title":"DNA Sequencing to Detect Residual Disease in Adults with Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant","volume":"329","author":"Dillon","year":"2023","journal-title":"JAMA"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41408-024-01078-8","article-title":"Multi-Target Measurable Residual Disease Assessed by Error-Corrected Sequencing in Patients with Acute Myeloid Leukemia: An ALFA Study","volume":"14","author":"Hirsch","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2017-02-735290","article-title":"Genetic Predisposition to Hematologic Malignancies: Management and Surveillance","volume":"130","author":"Godley","year":"2017","journal-title":"Blood"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/s41467-020-14829-5","article-title":"The Complex Genetic Landscape of Familial MDS and AML Reveals Pathogenic Germline Variants","volume":"11","author":"Vulliamy","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/jha2.1012","article-title":"Beyond Myeloid Neoplasms Germline Guidelines: Validation of the Thresholds Criteria in the Search of Germline Predisposition Variants","volume":"5","author":"Mestre","year":"2024","journal-title":"Ejhaem"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1097\/HS9.0000000000000321","article-title":"Nordic Guidelines for Germline Predisposition to Myeloid Neoplasms in Adults: Recommendations for Genetic Diagnosis, Clinical Management and Follow-Up","volume":"3","author":"Baliakas","year":"2019","journal-title":"HemaSphere"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/bjh.17855","article-title":"Integrating Germline Variant Assessment into Routine Clinical Practice for Myelodysplastic Syndrome and Acute Myeloid Leukaemia: Current Strategies and Challenges","volume":"196","author":"Tawana","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"e432218","DOI":"10.1200\/EDBK_432218","article-title":"Germline Predisposition in Hematologic Malignancies: Testing, Management, and Implications","volume":"Volume 44","author":"Godley","year":"2024","journal-title":"American Society of Clinical Oncology Educational Book"},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Farina, M., Bernardi, S., Gandolfi, L., Zanaglio, C., Morello, E., Turra, A., Zollner, T., Gramegna, D., Rambaldi, B., and Cattina, F. (2020). Case Report: Late Onset of Myelodysplastic Syndrome from Donor Progenitor Cells After Allogeneic Stem Cell Transplantation. Which Lessons Can We Draw from the Reported Case?. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.564521"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1038\/leu.2016.23","article-title":"Donor Cell-Derived Hematological Malignancy: A Survey by the Japan Society for Hematopoietic Cell Transplantation","volume":"30","author":"Kato","year":"2016","journal-title":"Leukemia"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1200\/JCO.21.02286","article-title":"Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation","volume":"40","author":"Gibson","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/bjh.18675","article-title":"Germline Predisposition to Haematological Malignancies: Best Practice Consensus Guidelines from the UK Cancer Genetics Group (UKCGG), CanGene-CanVar and the NHS England Haematological Oncology Working Group","volume":"201","author":"Speight","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1182\/blood.2022017739","article-title":"Predisposition to Myeloid Malignancies in Shwachman-Diamond Syndrome: Biological Insights and Clinical Advances","volume":"141","author":"Reilly","year":"2023","journal-title":"Blood"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1182\/hematology.2023000489","article-title":"Management of Fanconi Anemia beyond Childhood","volume":"2023","author":"Olson","year":"2023","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"20406207241257901","DOI":"10.1177\/20406207241257901","article-title":"Down Syndrome-Associated Leukaemias: Current Evidence and Challenges","volume":"15","author":"Mason","year":"2024","journal-title":"Ther. Adv. Hematol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1080\/17474086.2022.2140137","article-title":"Molecular Targets for the Treatment of AML in the Forthcoming 5th World Health Organization Classification of Haematolymphoid Tumours","volume":"15","author":"Molica","year":"2022","journal-title":"Expert. Rev. Hematol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1002\/hem3.145","article-title":"How to Manage Patients with Germline DDX41 Variants: Recommendations from the Nordic Working Group on Germline Predisposition for Myeloid Neoplasms","volume":"8","author":"Baliakas","year":"2024","journal-title":"HemaSphere"},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Ma, J., and Ross, S.R. (2024). Multifunctional Role of DEAD-Box Helicase 41 in Innate Immunity, Hematopoiesis and Disease. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1451705"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/blood.2022018221","article-title":"Germ Line DDX41 Mutations Define a Unique Subtype of Myeloid Neoplasms","volume":"141","author":"Makishima","year":"2023","journal-title":"Blood"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"2338509","DOI":"10.1080\/16078454.2024.2338509","article-title":"Combination Therapy with Venetoclax and Azacitidine for the Treatment of Myelodysplastic Syndromes with DDX41 Mutations","volume":"29","author":"Wang","year":"2024","journal-title":"Hematology"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/bjh.19105","article-title":"Venetoclax plus Hypomethylating Agents in DDX41-Mutated Acute Myeloid Leukaemia and Myelodysplastic Syndrome: Mayo Clinic Series on 12 Patients","volume":"204","author":"Nanaa","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1182\/bloodadvances.2021005738","article-title":"Genetic Features and Clinical Outcomes of Patients with Isolated and Comutated DDX41-Mutated Myeloid Neoplasms","volume":"6","author":"Alkhateeb","year":"2022","journal-title":"Blood Adv."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/s41375-021-01404-0","article-title":"AML with Germline DDX41 Variants Is a Clinicopathologically Distinct Entity with an Indolent Clinical Course and Favorable Outcome","volume":"36","author":"Li","year":"2022","journal-title":"Leukemia"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"106931","DOI":"10.1016\/j.leukres.2022.106931","article-title":"Comparison between GATA2 and DDX41-Mutated Myeloid Neoplasms","volume":"121","author":"Nanaa","year":"2022","journal-title":"Leuk. Res."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1002\/ajh.27497","article-title":"The Spectrum of Hematologic Neoplasms in Patients with Li-Fraumeni Syndrome","volume":"99","author":"Dimopoulos","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1182\/blood.2024025761","article-title":"GATA2 Links Stemness to Chemotherapy Resistance in Acute Myeloid Leukemia","volume":"145","author":"Alikarami","year":"2025","journal-title":"Blood"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1182\/blood.2022017764","article-title":"The Spectrum of GATA2 Deficiency Syndrome","volume":"141","author":"Calvo","year":"2023","journal-title":"Blood"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1182\/blood-2015-09-669937","article-title":"Prevalence, Clinical Characteristics, and Prognosis of GATA2-Related Myelodysplastic Syndromes in Children and Adolescents","volume":"127","author":"Wlodarski","year":"2016","journal-title":"Blood"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"7309","DOI":"10.1182\/blood-2024-202650","article-title":"GATA2-Mutated AML: Clinical Outcomes and Spectrum of Infections in Patients Undergoing or Not Allogeneic Stem Cell Transplantation","volume":"144","author":"Nicolet","year":"2024","journal-title":"Blood"},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Santiago, M., Liquori, A., Such, E., Z\u00fa\u00f1iga, \u00c1., and Cervera, J. (2023). The Clinical Spectrum, Diagnosis, and Management of GATA2 Deficiency. Cancers, 15.","DOI":"10.3390\/cancers15051590"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1182\/blood-2016-12-689109","article-title":"Runx Transcription Factors in the Development and Function of the Definitive Hematopoietic System","volume":"129","author":"Dzierzak","year":"2017","journal-title":"Blood"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/bloodadvances.2023011165","article-title":"Genomic Landscape of Patients with Germline RUNX1 Variants and Familial Platelet Disorder with Myeloid Malignancy","volume":"8","author":"Yu","year":"2024","journal-title":"Blood Adv."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.3324\/haematol.2012.064667","article-title":"RUNX1 Mutations in Cytogenetically Normal Acute Myeloid Leukemia Are Associated with a Poor Prognosis and Up-Regulation of Lymphoid Genes","volume":"97","author":"Greif","year":"2012","journal-title":"Haematologica"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.1182\/bloodadvances.2023010045","article-title":"Somatic Mutational Landscape of Hereditary Hematopoietic Malignancies Caused by Germline Variants in RUNX1, GATA2, and DDX41","volume":"7","author":"Homan","year":"2023","journal-title":"Blood Adv."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/ng.3253","article-title":"Germline Mutations in ETV6 Are Associated with Thrombocytopenia, Red Cell Macrocytosis and Predisposition to Lymphoblastic Leukemia","volume":"47","author":"Noetzli","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/ng.3177","article-title":"Germline ETV6 Mutations in Familial Thrombocytopenia and Hematologic Malignancy","volume":"47","author":"Zhang","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1182\/blood-2013-04-499319","article-title":"ANKRD26-Related Thrombocytopenia and Myeloid Malignancies","volume":"122","author":"Noris","year":"2013","journal-title":"Blood"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ajhg.2010.12.006","article-title":"Mutations in the 5\u2032 UTR of ANKRD26, the Ankirin Repeat Domain 26 Gene, Cause an Autosomal-Dominant Form of Inherited Thrombocytopenia, THC2","volume":"88","author":"Pippucci","year":"2011","journal-title":"Am. J. Hum. Genet."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"6673","DOI":"10.1182\/blood-2011-02-336537","article-title":"Mutations in ANKRD26 Are Responsible for a Frequent Form of Inherited Thrombocytopenia: Analysis of 78 Patients from 21 Families","volume":"117","author":"Noris","year":"2011","journal-title":"Blood"},{"key":"ref_179","doi-asserted-by":"crossref","unstructured":"Potenza, L., Borelli, E., Bigi, S., Giusti, D., Longo, G., Odejide, O., Porro, C.A., Zimmermann, C., Efficace, F., and Bruera, E. (2022). Early Palliative Care in Acute Myeloid Leukemia. Cancers, 14.","DOI":"10.3390\/cancers14030478"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/ajh.27584","article-title":"Treatment of Relapsed\/Refractory AML\u2014Novel Treatment Options Including Immunotherapy","volume":"100","author":"Moore","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Molica, M., Perrone, S., Andriola, C., and Rossi, M. (2023). Immunotherapy with Monoclonal Antibodies for Acute Myeloid Leukemia: A Work in Progress. Cancers, 15.","DOI":"10.3390\/cancers15205060"},{"key":"ref_182","doi-asserted-by":"crossref","unstructured":"Bruno, S., Borsi, E., Patuelli, A., Bandini, L., Mancini, M., Forte, D., Nanni, J., Barone, M., Grassi, A., and Cristiano, G. (2024). Tracking Response and Resistance in Acute Myeloid Leukemia through Single-Cell DNA Sequencing Helps Uncover New Therapeutic Targets. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms251810002"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1200\/JCO.2018.36.15_suppl.103","article-title":"Impact of Next-Generation Sequencing (NGS) on Treatment Selection in Acute Myeloid Leukemia (AML)","volume":"36","author":"Assi","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/CCO.0000000000000673","article-title":"A Precision Medicine Approach to Management of Acute Myeloid Leukemia in Older Adults","volume":"32","author":"Khanal","year":"2020","journal-title":"Curr. Opin. Oncol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"101533","DOI":"10.1016\/j.beha.2023.101533","article-title":"Cytogenetics and Genomics of Acute Myeloid Leukemia","volume":"37","author":"Snaith","year":"2024","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.jmoldx.2021.07.019","article-title":"The Application of Targeted RNA Sequencing for KMT2A-Partial Tandem Duplication Identification and Integrated Analysis of Molecular Characterization in Acute Myeloid Leukemia","volume":"23","author":"Dai","year":"2021","journal-title":"J. Mol. Diagn."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1182\/bloodadvances.2023010417","article-title":"Utility or Futility? A Contemporary Approach to Allogeneic Hematopoietic Cell Transplantation for TP53-Mutated MDS\/AML","volume":"8","author":"Nawas","year":"2024","journal-title":"Blood Adv."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1002\/cncr.33689","article-title":"Outcomes of TP53-Mutant Acute Myeloid Leukemia with Decitabine and Venetoclax","volume":"127","author":"Kim","year":"2021","journal-title":"Cancer"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood-2024-200413","article-title":"AML-MR Mutations Drive the Benefit of CPX-351 over 7 + 3 in the Pivotal Phase 3 AML Trial","volume":"144","author":"Shimony","year":"2024","journal-title":"Blood"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-024-01000-2","article-title":"Comparing Venetoclax in Combination with Hypomethylating Agents to Hypomethylating Agent-Based Therapies for Treatment Naive TP53-Mutated Acute Myeloid Leukemia: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)","volume":"14","author":"Badar","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood.2024024245","article-title":"TP53-Mutated Acute Myeloid Leukemia: How Can We Improve Outcomes?","volume":"145","author":"Sallman","year":"2025","journal-title":"Blood"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41573-022-00571-8","article-title":"Drugging P53 in Cancer: One Protein, Many Targets","volume":"22","author":"Hassin","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"223","DOI":"10.20517\/cdr.2022.130","article-title":"How Acute Myeloid Leukemia (AML) Escapes from FMS-Related Tyrosine Kinase 3 (FLT3) Inhibitors? Still an Overrated Complication?","volume":"6","author":"Perrone","year":"2023","journal-title":"Cancer Drug Resist."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1002\/ajh.70053","article-title":"Cytomolecular Mechanisms of Relapse and Post-Relapse Outcomes After Frontline FLT3 Inhibitor-Based Therapy in FLT3-Mutated AML","volume":"100","author":"Arora","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_195","doi-asserted-by":"crossref","unstructured":"Sasaki, K., Takahashi, S., Ouchi, K., Otsuki, Y., Wakayama, S., and Ishioka, C. (2023). Different Impacts of TP53 Mutations on Cell Cycle-Related Gene Expression among Cancer Types. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-32092-8"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1200\/JCO.24.00662","article-title":"Selection of Germline Genetic Testing Panels in Patients with Cancer: ASCO Guideline","volume":"42","author":"Tung","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1053\/j.seminhematol.2025.06.002","article-title":"AML Diagnostics in the 21st Century: Use of AI","volume":"62","author":"Haferlach","year":"2025","journal-title":"Semin. Hematol."},{"key":"ref_198","doi-asserted-by":"crossref","unstructured":"Qin, Y., Pu, X., Hu, D., and Yang, M. (2024). Machine Learning-Based Biomarker Screening for Acute Myeloid Leukemia Prognosis and Therapy from Diverse Cell-Death Patterns. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-68755-3"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/24\/8681\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T16:51:48Z","timestamp":1765212708000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/24\/8681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":198,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["jcm14248681"],"URL":"https:\/\/doi.org\/10.3390\/jcm14248681","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]}}}